These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36385940)

  • 21. Exploring conformation changes of Janus kinase 2 pseudokinase mediated by mutations through Gaussian accelerated molecular dynamics and principal component analysis.
    Bao H; He W; Chen J
    J Biomol Struct Dyn; 2023 Sep; ():1-18. PubMed ID: 37740650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
    Raivola J; Haikarainen T; Silvennoinen O
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress on the Pharmacological Targeting of Janus Pseudokinases.
    Henry SP; Jorgensen WL
    J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of imidazo[1,2-
    Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
    Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.
    Lindauer K; Loerting T; Liedl KR; Kroemer RT
    Protein Eng; 2001 Jan; 14(1):27-37. PubMed ID: 11287676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
    Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
    Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
    Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
    Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.
    Newton AS; Deiana L; Puleo DE; Cisneros JA; Cutrona KJ; Schlessinger J; Jorgensen WL
    ACS Med Chem Lett; 2017 Jun; 8(6):614-617. PubMed ID: 28626520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
    Wan S; Coveney PV
    J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
    Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression, characterization, and genomic structure of carp JAK1 kinase gene.
    Chang MS; Chang GD; Leu JH; Huang FL; Chou CK; Huang CJ; Lo TB
    DNA Cell Biol; 1996 Oct; 15(10):827-44. PubMed ID: 8892755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
    Chang Y; Xu S; Ding K
    J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
    Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
    Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the regulation and activation of JAK2: a novel hypothetical model.
    Lee TS
    Mol Cancer Res; 2013 Aug; 11(8):811-4. PubMed ID: 23615525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
    Zhong HA; Almahmoud S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
    Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
    Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
    Rusiñol L; Puig L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.